Position in HLN
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$37,110,438
-$15,451,640 QoQ
Shares Held
3,977,539
-24.3% QoQ
Ownership
0.090%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#24
of 639 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 87%
Shared 0%
None 13%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026BlackRock, Inc. holds $21,635,633,053 across 65 Drug Manufacturers - Specialty & Generic names. HLN ranks #32 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
5,294,529 | $2,868,734,637 | |
| 2 | ZTS |
Zoetis Inc.
|
39,430,181 | $2,833,452,797 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
13,711,607 | $2,310,954,234 | |
| 4 | TEVA |
Teva Pharmaceutical Industries Ltd
|
63,894,301 | $2,164,738,910 | |
| 5 | ALKS |
Alkermes plc.
|
29,235,739 | $1,531,952,715 | |
| 6 | VTRS |
Viatris Inc
|
86,019,468 | $1,365,989,144 | |
| 7 | ELAN |
Elanco Animal Health Inc
|
48,849,973 | $1,202,197,829 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
|
28,703,514 | $995,150,823 |
All Filings in HLN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $37,110,438 | 3,977,539 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $52,562,078 | 5,250,957 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $50,380,211 | 4,983,206 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $56,062,301 | 6,249,978 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $66,610,500 | 6,423,385 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $42,437,595 | 4,124,159 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $34,902,595 | 3,658,553 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $32,119,896 | 3,035,907 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||